Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Update

Abeona Therapeutics Inc (NASDAQ:ABEO) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,760,000 shares, an increase of 24.9% from the March 31st total of 2,210,000 shares. Based on an average daily volume of 556,500 shares, the short-interest ratio is presently 5.0 days. Currently, 6.4% of the company’s shares are sold short.

Abeona Therapeutics Stock Up 4.7 %

Shares of NASDAQ ABEO opened at $6.87 on Friday. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a market cap of $335.26 million, a PE ratio of -2.55 and a beta of 1.71. The company’s fifty day simple moving average is $5.06 and its 200 day simple moving average is $5.62. Abeona Therapeutics has a 12-month low of $3.84 and a 12-month high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.19. As a group, sell-side analysts forecast that Abeona Therapeutics will post -1.16 earnings per share for the current fiscal year.

Insider Transactions at Abeona Therapeutics

In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the sale, the chief executive officer now owns 1,355,322 shares of the company’s stock, valued at approximately $6,478,439.16. This represents a 1.81 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Abeona Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP bought a new position in shares of Abeona Therapeutics in the 4th quarter worth $520,000. Trexquant Investment LP acquired a new position in Abeona Therapeutics during the fourth quarter worth $382,000. Jane Street Group LLC bought a new position in shares of Abeona Therapeutics in the third quarter valued at $84,000. JPMorgan Chase & Co. grew its holdings in shares of Abeona Therapeutics by 74.2% during the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after buying an additional 28,606 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock valued at $2,942,000 after buying an additional 83,050 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ABEO. Oppenheimer initiated coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 target price on the stock. HC Wainwright boosted their price objective on Abeona Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 24th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Abeona Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $18.75.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.